PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
+36.97%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$390M
AUM Growth
+$390M
(+3.3%)
Cap. Flow
-$61.3M
Cap. Flow
% of AUM
-15.71%
Top 10 Holdings %
Top 10 Hldgs %
30.29%
Holding
100
New
16
Increased
29
Reduced
38
Closed
17
Top Buys
| 1 |
Schrodinger
SDGR
|
$8.4M |
| 2 |
Arrowhead Research
ARWR
|
$5.15M |
| 3 |
DexCom
DXCM
|
$4.42M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$4.26M |
| 5 |
Avantor
AVTR
|
$4.25M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$12.7M |
| 2 |
Merck
MRK
|
$10.4M |
| 3 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$9.03M |
| 4 |
Masimo
MASI
|
$8.26M |
| 5 |
Edwards Lifesciences
EW
|
$6.56M |
Sector Composition
| 1 | Healthcare | 92.05% |
| 2 | Technology | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EIDX
51
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $2.84M | 0.73% | 21,609 -19,482 | -47% | -$2.56M |
|
52
Immunovant
IMVT
$2.56B
| $2.81M | 0.72% | 60,781 -89,370 | -60% | -$4.13M |
|
53
Axsome Therapeutics
AXSM
$6.05B
| $2.51M | 0.64% | 30,758 -4,252 | -12% | -$346K |
|
|
TRIL
54
DELISTED
Trillium Therapeutics Inc.
TRIL
| $2.42M | 0.62% | 164,585 -210,478 | -56% | -$3.1M |
|
55
89bio
ETNB
$1.34B
| $2.36M | 0.6% | 96,673 -13,327 | -12% | -$325K |
|
56
BioMarin Pharmaceuticals
BMRN
$11.2B
| $2.19M | 0.56% | +25,000 | New | +$2.19M |
|
|
SDC
57
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
| $2.1M | 0.54% | 175,691 -184,309 | -51% | -$2.2M |
|
|
BCEL
58
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $2.04M | 0.52% | 126,258 +91,258 | +261% | +$1.47M |
|
59
KALA BIO
KALA
$78.8M
| $1.85M | 0.47% | 272,445 -37,608 | -12% | -$255K |
|
|
ONCT
60
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $1.85M | 0.47% | +376,779 | New | +$1.85M |
|
|
TECX
61
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $1.69M | 0.43% | 121,018 -39,606 | -25% | -$552K |
|
|
SURF
62
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $1.62M | 0.42% | 175,792 -24,227 | -12% | -$224K |
|
63
Outset Medical
OM
$247M
| $1.6M | 0.41% | 28,211 +21,211 | +303% | +$1.21M |
|
64
Curis
CRIS
$20.9M
| $1.6M | 0.41% | +195,000 | New | +$1.6M |
|
65
Castle Biosciences
CSTL
$696M
| $1.53M | 0.39% | 22,831 -7,172 | -24% | -$482K |
|
|
MTEM
66
DELISTED
Molecular Templates, Inc.
MTEM
| $1.5M | 0.39% | 160,112 -107,826 | -40% | -$1.01M |
|
67
Madrigal Pharmaceuticals
MDGL
$9.76B
| $1.44M | 0.37% | 12,976 -5,235 | -29% | -$582K |
|
68
Nephros
NEPH
$39.5M
| $1.43M | 0.37% | 167,048 -74,363 | -31% | -$638K |
|
|
PROF
69
Profound Medical
PROF
$134M
| $1.42M | 0.36% | 69,049 -951 | -1% | -$19.6K |
|
70
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $1.33M | 0.34% | +75,000 | New | +$1.33M |
|
71
Aurinia Pharmaceuticals
AUPH
$1.58B
| $1.24M | 0.32% | 89,503 -40,809 | -31% | -$564K |
|
72
Gyre Therapeutics
GYRE
$703M
| $1.19M | 0.31% | 189,161 -19,317 | -9% | -$122K |
|
73
Forte Biosciences
FBRX
$137M
| $1.13M | 0.29% | 31,098 +18,598 | +149% | +$677K |
|
74
Altimmune
ALT
$338M
| $1.13M | 0.29% | +100,000 | New | +$1.13M |
|
|
BLRX
75
BioLineRX
BLRX
$16.2M
| $1.08M | 0.28% | +427,943 | New | +$1.08M |
|